It will be crucial to investigate MYC alterations in FGFR3 aberrant urothelial bladder cancer, as it may provide further insight into the pathogenesis of bladder cancer, and it could also have therapeutic implications. The gene discussed is MYC; the disease is bladder transitional cell carcinoma.